has the fda approved 25 mg of psilocybin, or 2.5 g of mushrooms, as a standard dose?
“The FDA has approved 25 millig or 2.5 g of mushrooms as the standard dose. That's why most all clinical trials are 25 milligrams.”
a guest, a mycologist said on Huberman Lab, 2026-11-16, at 1:39:28. hear it in context → the speaker cited: the FDA.
first, the part that holds
25 mg of synthetic psilocybin is the dose used in the late-stage industry trials, including both phase 3 trials behind the first psilocybin application now before the FDA. At an average potency of about 1%, 2.5 g of dried mushrooms works out to roughly 25 mg on paper.
what we found when we went and looked
we found no FDA approval of any psilocybin dose. The sponsor of the leading candidate states in its quarterly SEC filing for the period ending 30 september 2026 that it has no product approved for sale and that its new drug application is still under rolling review. The FDA's final psychedelic guidance (july 2026) is nonbinding and names no dose. It tells sponsors to "characterize the dose-response relationship" themselves. Mushrooms have never been under FDA review in any form, and a 2026 analysis of 14 strains found psilocybin content ranging from about 2 to 19.6 mg per gram, so 2.5 g has no fixed equivalent.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the FDA has approved 25 mg of psilocybin as a standard dose | false | the sponsor's 10-Q for the quarter ending 30 sept 2026 says: "We do not have any therapeutic candidates approved for sale." It also says the FDA's rolling review of its NDA "is ongoing" and that approval and rescheduling "remains necessary." The FDA's july 2026 guidance sets no dose and says psychedelics like psilocybin are mostly schedule I, with "no currently accepted medical use." Limitation: that filing covers the period through 30 september. The sponsor has since said it completed the NDA, and a fast review was targeted. We found no approval as of 17 nov 2026, but this could change soon, and any approval would cover one labeled product, not a general standard dose. [1][2][3] |
| 2.5 g of mushrooms equals 25 mg of psilocybin, and the FDA approved that amount | overstated | a 2026 study of 14 cultivated strains found an average of about 1% psilocybin (about 10 mg/g), so the conversion holds as a rough average. But strains ranged from about 2.03 to 19.60 mg/g, meaning 2.5 g could hold anywhere from about 5 to 49 mg, and individual mushrooms within one strain varied by 13–23% (coefficient of variation). Under the FDA guidance, mushroom material would count as a botanical, and no botanical psilocybin product is under approval. The trial products are synthetic psilocybin. [2][5] |
| that is why most clinical trials use 25 mg | misattributed | 25 mg is common: both of the sponsor's phase 3 trials used it (one dose, or two doses three weeks apart), as did a 104-person phase 2 trial in JAMA (2023). But these trials picked the dose before any FDA approval existed, so an FDA approval can't explain the choice. FDA guidance leaves dose-finding to sponsors. Some trials also dose by body weight: a JAMA Psychiatry trial used 20 mg/70 kg, then 30 mg/70 kg. [2][3][4] |
| 25 mg is the most common dose in recent psilocybin trials for depression | confirmed | in the records we read, it is the dose in the sponsor's phase 3 trials (COMP005, COMP006) and in the JAMA 2023 trial. We did not systematically count every trial, so 'most all' is plausible but not measured here. [3] |
both directions
for the speaker: 25 mg really is the dose that late-stage psilocybin trials have settled on, including both phase 3 trials in the pending FDA application and a multisite phase 2 trial published in JAMA. So if the FDA approves the pending product, 25 mg is the likely labeled dose. The conversion to 2.5 g of mushrooms matches the roughly 1% average psilocybin content found in a 2026 analysis of cultivated mushrooms.
against: no psilocybin product had FDA approval in the records we read. The sponsor's own SEC filing says it has nothing approved for sale and that the review is ongoing. The FDA's final guidance names no dose and asks sponsors to work out the dose-response themselves, so the FDA did not set 25 mg. The causation runs the other way: trials chose 25 mg, and any approval would follow from that. The FDA has never considered mushrooms at all. And because mushroom potency varies almost tenfold between strains, a gram figure can't stand in for a milligram dose. Some academic trials also dose by body weight rather than a flat 25 mg.
what this cannot say
the SEC filing covers the period through 30 september 2026, and the pending application had a fast-track voucher, so an approval could come shortly after this check. If it does, the main clause changes from never approved to recently approved for one product, but it would still not be an approved standard dose of mushrooms. We did not count every registered psilocybin trial, so 'most trials use 25 mg' rests on the late-stage trials we read, not a census. The mushroom potency figures come from one 14-strain cultivation study and don't cover wild or stored material.
sources, each one fetched and read
- U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations (guidance index page), docket FDA-2023-D-1987, final July 2026 What we read there: lists the guidance as final, finalizing the june 2023 draft, docket FDA-2023-D-1987, content current as of 07/13/2026. Fetched 2026-11-17 (HTTP 200). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations
- U.S. Food and Drug Administration, CDER, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry, July 2026 (PDF) What we read there: "Sponsors should plan to characterize the dose-response relationship for both safety and efficacy early in the drug development program." Many psychedelic drugs are schedule I with "no currently accepted medical use"; mushroom material "may be considered a botanical". No dose of psilocybin is specified anywhere in the document. Fetched 2026-11-17 (HTTP 200). https://www.fda.gov/media/169694/download
- psilocybin sponsor, Form 10-Q for the quarter ended September 30, 2026, filed with the U.S. Securities and Exchange Commission What we read there: "We do not have any therapeutic candidates approved for sale"; the FDA "granted our request for a rolling review of our NDA, which is ongoing"; regulatory approval and rescheduling "remains necessary"; phase 3 COMP005 used "a single dose (25mg)" and COMP006 "two fixed doses, administered 3 weeks apart, of COMP360 25 mg versus 1 mg." Fetched 2026-11-17 (HTTP 200). https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000076/cmps-20260930.htm
- Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 2021 (PMC7643046) What we read there: "The psilocybin dose was moderately high (20 mg/70 kg) in session 1 and was high (30 mg/70 kg) in session 2." Fetched 2026-11-17 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC7643046/
- Surprising variability in tryptamine profiles of Psilocybe cubensis fruiting bodies: inter- and intra-strain differences across 14 strains cultivated under controlled conditions. Journal of Fungi, 2026;12(7):486 (PMC13412672) What we read there: average psilocybin "approximately 1%, equivalent to about 10 mg/g in dried material"; strains ranged from about 2.03 to 19.60 mg/g; coefficient of variation between individual fruiting bodies 12.81% to 23.39%. Fetched 2026-11-17 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC13412672/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam